| 王丽华,孙秀佳,于文娟,卢卫红.精神分裂症患者中的高泌乳素血症研究进展[J].,2020,(2):397-400 |
| 精神分裂症患者中的高泌乳素血症研究进展 |
| Progress in Research on Hyperprolactinemia in Patients with Schizophrenia |
| 投稿时间：2018-12-28 修订日期：2019-01-25 |
| DOI：10.13241/j.cnki.pmb.2020.02.041 |
| 中文关键词: 精神分裂症 高泌乳素血症 抗精神病药物 |
| 英文关键词: Schizophrenia Hyperprolactinemia Antipsychotics |
| 基金项目:上海市卫生和计划生育委员会项目（201740089；20144Y0080）；上海交通大学医学院转化医学协同创新中心合作研究项目 (TM201506, TM201624)； 国家"重大新药创制"科技重大专项(2018ZX09734-005)；上海高校高峰高原学科建设-上海交大医学院项目（DLY201620） |
|
| 摘要点击次数: 668 |
| 全文下载次数: 552 |
| 中文摘要: |
| 摘要：高泌乳素血症在精神分裂症患者中发生率高，主要原因为抗精神病药物和精神分裂症本身的作用。精神分裂症患者服用抗精神病药物后泌乳素水平较快升高，长期服用后泌乳素水平可能趋向于稳定甚至降低，但仍高于正常值。高泌乳素血症会导致肥胖等诸多不良后果。而精神分裂症患者服用抗精神病药物后另一常见的副反应是代谢相关不良反应，越来越多的研究开始关注兼顾治疗高泌乳素血症及肥胖、糖脂代谢异常的方法。溴隐亭、阿立哌唑及芍药甘草汤等中药具有一定的降低泌乳素水平的作用，但使用有限制性，且不能改善抗精神病药物所致代谢相关的不良反应。二甲双胍除了能改善糖脂代谢紊乱，还具有潜在的降泌乳素作用，对于同时有代谢异常如肥胖、糖脂代谢异常及高泌乳素血症的患者来说可能具有双重治疗效果，但其降泌乳素的疗效和剂量需要进一步的大样本临床研究。 |
| 英文摘要: |
| ABSTRACT: Hyperprolactinemia has a high incidence in schizophrenia patients, and the main causes are the effect of antipsychotics and schizophrenia itself. Prolactin levels are rapidly increased in patients with schizophrenia after taking antipsychotic drugs. Prolactin levels may tend to stabilize or even decrease after long-term use of antipsychotic drugs, but still higher than normal. Hyperprolactinemia can lead to many adverse consequences such as obesity. Another common side effect of antipsychotic drugs in patients with schizophrenia is adverse effect related to metabolism. More and more studies have begun to pay attention to the treatment of hyperprolactinemia and obesity, abnormal glucose and lipid metabolism. Bromocriptine, aripiprazole and traditional Chinese medicines such as peony licorice have certain effects on reducing prolactin levels, but their use is restrictive and cannot improve the adverse effect related to metabolism caused by antipsychotic drugs. In addition to improving glucose and lipid metabolism disorders, metformin also has a potential prolactin effect, which may have dual therapeutic effects in patients with obesity, abnormal glucose and lipid metabolism and hyperprolactinemia, but its effect and doses of reducing prolactin levels require further large sample clinical studies. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
